Kityo C, Mambule IK, Musaazi J, Sokhela S, et al. Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial. Lancet Infect Dis 2024 May 28:S1473-3099(24)00289.
PMID: 38821073